Pioglitazone in the treatment of major depressio
Phase 2
- Conditions
- Major Depressive episode.Major Depressive episode
- Registration Number
- IRCT201012031556N20
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Presence of Major Depressive Disorder based on DSM-IV criteria, Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22. Exclusion criteria: Presence of Psychosis, any other diagnosis in Axis I and II, Receiving psychotropic medications, receiving any antidepressants during past one month or ECT during past two months, Presence of hypothyroidism or cardiovascular problems, pregnancy or nursing women
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of depression. Timepoint: Baseline and weeks 2,4 and 6. Method of measurement: Hamiltion Depression Rating Scale 17-Item.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pioglitazone's PPAR-γ activation in major depression treatment?
How does pioglitazone adjuvant therapy compare to SSRIs/SNRIs in treating major depressive episodes?
Which biomarkers predict response to pioglitazone as an adjuvant for major depression?
What are the potential adverse events of pioglitazone in depression and their management strategies?
Are there combination therapies involving pioglitazone and other antidepressants for major depression?